McKesson (MCK)
(Delayed Data from NYSE)
$485.42 USD
+3.15 (0.65%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$485.42 USD
+3.15 (0.65%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
Insulet (PODD) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Insulet's (PODD) fourth-quarter 2021 revenues improved year over year on a strong performance of Omnipod, both in U.S. and international markets.
NuVasive (NUVA) Q4 Earnings Miss Estimates, Gross Margin Up
by Zacks Equity Research
Continued strong international performance and introduction of products drove NuVasive's (NUVA) revenues in the fourth quarter of 2021.
Amedisys (AMED) Q4 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Robust performances by the Home Health and Hospice segments drove Amedisys' (AMED) fourth-quarter top line.
Exact Sciences (EXAS) Q4 Revenues Top Estimates, Margin Down
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business saw strong momentum on solid Cologuard volume growth during the fourth quarter.
Tandem Diabetes (TNDM) Q4 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Robust domestic and international pump shipments are driving Tandem Diabetes' (TNDM) fourth-quarter top line.
Charles River (CRL) DSA Arm Sees Growth, Cell Supply Sluggish
by Zacks Equity Research
The acquisitions of Cognate BioServices and Vigene Biosciences contribute to the growth of Charles River's (CRL) Manufacturing Solutions arm.
Henry Schein (HSIC) Up 10.1% Since Posting Q4 Earnings Beat
by Zacks Equity Research
Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.
Syneos Health (SYNH) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Syneos Health (SYNH) reports better-than-expected earnings for the fourth quarter and strong performances by the Clinical Solutions and Commercial Solutions arms.
Globus Medical (GMED) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Strength in Musculoskeletal Solutions and Enabling Technologies products drove Globus Medical's (GMED) Q4 revenues.
What Makes McKesson (MCK) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does McKesson (MCK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Grow
by Zacks Equity Research
Robust performances by all three operating businesses drove Henry Schein's (HSIC) Q4 revenues.
Omnicell (OMCL) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Robust performance by the Product and Service segments is driving Omnicell's (OMCL) fourth-quarter top line.
Should Value Investors Buy These Medical Stocks?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Reasons Why McKesson (MCK) Is a Great Growth Stock
by Zacks Equity Research
McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
If You Invested $1000 in McKesson 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Surging Earnings Estimates Signal Upside for McKesson (MCK) Stock
by Zacks Equity Research
McKesson (MCK) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Are These Medical Stocks a Great Value Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Ideas feature highlights: Henry Schein, AmerisourceBergen and McKesson
by Zacks Equity Research
Henry Schein, AmerisourceBergen and McKesson are included in this Investment Ideas blog.
The Stock-Picking Puzzle: Putting The Pieces Together
by Bryan Hayes
The Stock-Picking Puzzle: Putting The Pieces Together
Company News for Feb 4, 2022
by Zacks Equity Research
Companies In The News Are: TMUS, MCK, ALL, AFL.
McKesson (MCK) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter 2022 results benefit from considerable growth across all segments.
McKesson (MCK) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 14.31% and 3.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Feb 2: BSX, TMO & More
by Riya Anand
Medical Products companies' Q4 results are likely to reflect an increase in COVID-19 testing demand. Let's see how BSX, TMO, HOLX and MCK are poised ahead of their earnings releases.
McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Is a Surprise Coming for McKesson (MCK) This Earnings Season?
by Zacks Equity Research
McKesson (MCK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.